Axitinib

EGFR Inhibitor

DB06626

Approved Indication

Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.

3 Targets

0 Resistance Mutations

5 References

4AG8 Structure Loaded

3D Structure PDB: 4AG8

Switch structure: RCSB ↗

Protein Targets

Mechanism of Action

Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.

Details

DrugBank ID DB06626 ↗

Approval Date 2012-01-27

Molecular Weight 386.47 g/mol

Drug Class EGFR Inhibitor

ATC Codes L01XE17

Synonyms axitinib, axitinibum

SMILES

[H]\C(=C(\[H])C1=CC=CC=N1)C1=C2C=CC(SC3=CC=CC=C3C(O)=NC)=CC2=NN1

ADMET Profile

Computing properties…

Drug References (DrugBank)